论文部分内容阅读
目的探讨瑞舒伐他汀和阿托伐他汀治疗冠心病的临床效果。方法 102例冠心病患者,按照随机数字表法分为研究组与对照组,各51例。在常规治疗的基础上,对照组患者给予阿托伐他汀治疗,研究组患者给予瑞舒伐他汀治疗。对比两组患者临床疗效和心功能分级疗效。结果研究组患者治疗总有效率为98.0%,明显高于对照组的78.4%(P<0.05);研究组患者心功能分级总有效率为98.0%,明显高于对照组的76.5%(P<0.05)。结论瑞舒伐他汀在冠心病治疗中较阿托伐他汀有着更为显著的效果,能明显改善患者的心功能及预后,值得进行深入研究和推广。
Objective To investigate the clinical effect of rosuvastatin and atorvastatin on coronary heart disease. Methods A total of 102 patients with coronary heart disease were divided into study group and control group according to the random number table, each with 51 cases. On the basis of routine treatment, patients in the control group were given atorvastatin, and patients in the study group were given rosuvastatin. The clinical efficacy and cardiac function of two groups were compared. Results The total effective rate of study group was 98.0%, significantly higher than 78.4% of control group (P <0.05). The total effective rate of study group was 98.0%, significantly higher than that of control group (76.5%, P < 0.05). Conclusion Rosuvastatin has more significant effect than atorvastatin in the treatment of coronary heart disease, which can significantly improve the cardiac function and prognosis of patients, which deserves further study and promotion.